Movement Alert｜ImmunityBio Falls 5.12% in Regular Trading, FDA Warning Letter Continues to Suppress Market Confidence

Market Focus06-17

On June 17, ImmunityBio fell 5.12% in regular trading, trading at $6.765/share, with turnover of $68.427 million. The decline is primarily attributed to ongoing pressure from an FDA warning letter targeting the company's marketing practices for its core drug Anktiva.

The FDA's Office of Prescription Drug Promotion (OPDP) issued a formal warning letter citing misleading promotional practices for Anktiva (nogapendekin alfa inbakicept-pmln), an IL-15 receptor agonist designed to promote NK cell and CD8+ T cell proliferation. This marks the first formal warning letter from OPDP this year, following two prior untitled letters issued to the company's subsidiary Altor BioScience. Although ImmunityBio has responded with clarifications and corrective actions — noting the controversial TV advertisement was never publicly aired and removing disputed podcast content — compliance risks continue to weigh on sentiment.

The stock faces compounded headwinds from post-ASCO profit-taking pressure after clinical catalysts were realized in late May. With the company still operating at a loss, market confidence in its commercialization outlook remains challenged.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179214586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 03:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179214586","market":"us","top_or_hot":-1,"title":"Movement Alert｜ImmunityBio Falls 5.12% in Regular Trading, FDA Warning Letter Continues to Suppress Market Confidence","media":"Market Focus","content":"<p><p>On June 17, ImmunityBio fell 5.12% in regular trading, trading at $6.765/share, with turnover of $68.427 million. The decline is primarily attributed to ongoing pressure from an FDA warning letter targeting the company's marketing practices for its core drug Anktiva.</p><p>The FDA's Office of Prescription Drug Promotion (OPDP) issued a formal warning letter citing misleading promotional practices for Anktiva (nogapendekin alfa inbakicept-pmln), an IL-15 receptor agonist designed to promote NK cell and CD8+ T cell proliferation. This marks the first formal warning letter from OPDP this year, following two prior untitled letters issued to the company's subsidiary Altor BioScience. Although ImmunityBio has responded with clarifications and corrective actions — noting the controversial TV advertisement was never publicly aired and removing disputed podcast content — compliance risks continue to weigh on sentiment.</p><p>The stock faces compounded headwinds from post-ASCO profit-taking pressure after clinical catalysts were realized in late May. With the company still operating at a loss, market confidence in its commercialization outlook remains challenged.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ImmunityBio Falls 5.12% in Regular Trading, FDA Warning Letter Continues to Suppress Market Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ImmunityBio Falls 5.12% in Regular Trading, FDA Warning Letter Continues to Suppress Market Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-17 03:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 17, ImmunityBio fell 5.12% in regular trading, trading at $6.765/share, with turnover of $68.427 million. The decline is primarily attributed to ongoing pressure from an FDA warning letter targeting the company's marketing practices for its core drug Anktiva.</p><p>The FDA's Office of Prescription Drug Promotion (OPDP) issued a formal warning letter citing misleading promotional practices for Anktiva (nogapendekin alfa inbakicept-pmln), an IL-15 receptor agonist designed to promote NK cell and CD8+ T cell proliferation. This marks the first formal warning letter from OPDP this year, following two prior untitled letters issued to the company's subsidiary Altor BioScience. Although ImmunityBio has responded with clarifications and corrective actions — noting the controversial TV advertisement was never publicly aired and removing disputed podcast content — compliance risks continue to weigh on sentiment.</p><p>The stock faces compounded headwinds from post-ASCO profit-taking pressure after clinical catalysts were realized in late May. With the company still operating at a loss, market confidence in its commercialization outlook remains challenged.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1179214586","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179214586","pubTimestamp":1781638100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 17, ImmunityBio fell 5.12% in regular trading, trading at $6.765/share, with turnover of $68.427 million. The decline is primarily attributed to ongoing pressure from an FDA warning letter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"动向提示|ImmunityBio常规交易跌5.12%FDA警告信继续打压市场信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"On June 17, ImmunityBio fell 5.12% in regular trading, trading at $6.765/share, with turnover of $68.427 million. The decline is primarily attributed to ongoing pressure from an FDA warning letter targeting the company's marketing practices for its core drug Anktiva.The FDA's Office of Prescription Drug Promotion (OPDP) issued a formal warning letter citing misleading promotional practices for Anktiva (nogapendekin alfa inbakicept-pmln), an IL-15 receptor agonist designed to promote NK cell and CD8+ T cell proliferation. This marks the first formal warning letter from OPDP this year, following two prior untitled letters issued to the company's subsidiary Altor BioScience. Although ImmunityBio has responded with clarifications and corrective actions — noting the controversial TV advertisement was never publicly aired and removing disputed podcast content — compliance risks continue to weigh on sentiment.The stock faces compounded headwinds from post-ASCO profit-taking pressure after clinical catalysts were realized in late May. With the company still operating at a loss, market confidence in its commercialization outlook remains challenged.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179214586","isCrawlerRequest":true}